Aquacelle® Omega 3: Participants will consume 1 capsule containing 315mg EPA and DHA
Comparator Omega 3: Participants will consume 1 capsule containing 315mg EPA and DHA
Plexosome® Vitamin D3: Participants will have 1000IU vitamin D3 each day for 7 days
Comparator Vitamin D3: Participants will have 1000IU vitamin D3 each day for 7 days
Plexosome® Vitamin D3 6 weeks: Participants will have 1000IU vitamin D3 each day for 6 weeks
Comparator Vitamin D3 6 weeks: Participants will have 1000IU vitamin D3 each day for 6 weeks
Study summary
The goal of this interventional study is to compare the absorption of supplements with and without absorption enhancing technology in healthy volunteers. We will be testing vitamin D3 and omega 3 in both males and females 18 years and older. Part A will comprise of two arms receiving a single dose of omega-3 supplement, and two arms who will receive vitamin D3 supplement daily for 7 days. Part B comprises of two arms who will receive vitamin D3 supplement daily for 6 weeks.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Part A:
Inclusion Criteria:
* Adults 18 years and older
* Generally healthy
* BMI 18.5-29.9 kg/m2
* Able to provide informed consent
* Agree to not participate in another clinical trial while enrolled in this trial
* Agree not to change current diet and/or exercise frequency or intensity during entire study period
* Participant's ability to participate fully and comply with demands of the study including attendance at all scheduled blood collection time points
Exclusion Criteria:
* Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions
* Have an unstable illness e.g. diabetes and thyroid gland dysfunction
* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
* Significant change in diet in the past 1-month (e.g., removal of a food group or calorie restriction)
* Active smokers, nicotine use or drug (prescription or illegal substances) abuse
* Chronic past and/or current alcohol use (\>21 alcoholic drinks week)
* Pregnant or lactating women
* Allergic to any of the ingredients in enhanced or standard formula
* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month (excluding RDC Clinical trials)
* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion
* Regular use within the past 4 weeks of supplements containing the trial product
Part B:
The above criteria apply, plus baseline serum 25(OH)D \<20.0 ng/mL (\<50.0 nm/L)
Primary outcome measure(s)
Part A: serum/plasma absorption (AUC) of the trial product t0-t168 (vitamin D3) — Baseline to day 7 Baseline-corrected values in serum/plasma absorption (AUC) of the trial product t0-t168 (vitamin D3)
Part A: serum/plasma absorption (AUC) of the trial product t0-t24 (omega-3) — Baseline to day 2 Baseline-corrected values in serum/plasma absorption (AUC) of the trial product t0-t24 (omega-3)
Part B: Baseline-corrected serum 25(OH)D AUC (0-6 weeks) — Baseline to 6 weeks Baseline-corrected serum 25(OH)D AUC (0-6 weeks)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.